Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 54,948 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Patient Clear all
Recruiting No phase listed Observational

This Study Will Evaluate Cardiorespiratory and Muscular Fitness to Examine Associations With Anthropometric Characteristics and Other Indicators of Cardiometabolic Risk Among Patients With or Without Autism Spectrum Disorder

NCT07804680
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Cardiometabolic Health Indicators, Cardiometabolic Risk Factors, Metabolic Syndrome, Prediabetes
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 7, 2026, 2:38 PM EST
Completed No phase listed Observational

Pulmonary Hypertension in Trisomy 21 Patients

NCT00478296
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 8 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Nov 7, 2026, 2:38 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

NCT03898479
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Nov 7, 2026, 2:38 PM EST
Completed Phase 2 Interventional Results available

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT03845296
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Rucaparib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
950
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Nov 7, 2026, 2:38 PM EST
Not yet recruiting Phase 4 Interventional

Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis

NCT07682662
View directory record Official record
Conditions
Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD)
Interventions
Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm)
Drug · Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
2 Years to 21 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 7, 2026, 2:38 PM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Clinical Effect of Caffeine Consumption in Patients Taking Oral Terbinafine

NCT05667246
View directory record Official record
Conditions
Terbinafine Adverse Reaction
Interventions
Caffeinated Coffee, Decaffeinated Coffee
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 7, 2026, 2:38 PM EST
Completed No phase listed Observational

Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission

NCT00801346
View directory record Official record
Conditions
Fatigue, Leukemia, Long-term Effects Secondary to Cancer Therapy in Children
Interventions
laboratory biomarker analysis, metabolic assessment, questionnaire administration, assessment of therapy complications, fatigue assessment and management, quality-of-life assessment
Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Year to 20 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Nov 7, 2026, 2:38 PM EST
Terminated Phase 2 Interventional Results available

PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer

NCT04099888
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
Fimaporfin and Gemcitabine, Gemcitabine/Cisplatin chemotherapy
Drug
Lead sponsor
PCI Biotech AS
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Nov 7, 2026, 2:38 PM EST
Terminated Phase 2 Interventional Results available

Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer

NCT00256308
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Oxaliplatin, Radiation
Drug · Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Nov 7, 2026, 2:38 PM EST
Completed Phase 2 Interventional Results available

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

NCT02228525
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
selinexor (KPT-330)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Nov 7, 2026, 2:38 PM EST
Completed Phase 2 Interventional Results available

A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL

NCT00858117
View directory record Official record
Conditions
Leukemia
Interventions
Alemtuzumab, Rituximab
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Nov 7, 2026, 2:38 PM EST
Completed Phase 4 Interventional Results available

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis

NCT01382940
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
rituximab, methotrexate, methylprednisolone, acetaminophen, antihistamine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
86
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Nov 7, 2026, 2:38 PM EST
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Nov 7, 2026, 2:38 PM EST
Completed No phase listed Observational

Identification and Treatment of Men With BPH in the Primary Care Setting

NCT00211640
View directory record Official record
Conditions
No Conditions for This Study. All Male Patients 18 Years of Age or Older Were Administered the LUTS, MSHQ, and Patient Demographics Questionnaire
Interventions
Not listed
Lead sponsor
Mid Michigan Health Centers
Other
Eligibility
18 Years and older · Male only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Jackson, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 21, 2005 · Synced Nov 7, 2026, 2:38 PM EST
Not yet recruiting Not applicable Interventional

Vibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients

NCT05558189
View directory record Official record
Conditions
Parkinson Disease
Interventions
Vibrotactile Coordinated Reset (vCR)
Device
Lead sponsor
Stanford University
Other
Eligibility
35 Years to 92 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Nov 7, 2026, 2:38 PM EST
Completed Phase 2 Interventional Results available

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

NCT04585789
View directory record Official record
Conditions
Hepatitis B
Interventions
JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Nov 7, 2026, 2:38 PM EST
Terminated No phase listed Observational

A Pilot Study to Evaluate the Contribution of the Saphenous Nerve in Ankle Pain of Patients With Degenerative Joint Disease of the Ankle

NCT01716650
View directory record Official record
Conditions
Degenerative Joint Disease of the Ankle
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Nov 7, 2026, 2:38 PM EST
Completed Phase 3 Interventional

A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients

NCT00000991
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Dapsone, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
20
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 7, 2026, 2:38 PM EST
Withdrawn Phase 1 Interventional

Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation

NCT01483274
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Vaccine
Biological
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Nov 7, 2026, 2:38 PM EST
Completed Phase 3 Interventional Results available

Analgesic Efficacy of Repeated Doses of Intravenous (IV) Acetaminophen in Post-operative Pediatric Spine Fusion Patients

NCT01394718
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Intravenous Acetaminophen, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 18 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Nov 7, 2026, 2:38 PM EST
Completed Phase 1 Interventional

Study of MEDI 507 in the Treatment of Pediatric Patients

NCT00813618
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
MEDI-507
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
6
States / cities
Birmingham, Alabama • Orange, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2008 · Synced Nov 7, 2026, 2:38 PM EST
Completed Phase 2 Interventional Results available

Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

NCT00597818
View directory record Official record
Conditions
NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
Interventions
Cobiprostone, Placebo, Non-steroidal anti-inflammatory drug
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
40 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Phoenix, Arizona • Chula Vista, California • Loma Linda, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Nov 7, 2026, 2:38 PM EST
Completed No phase listed Observational Results available

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

NCT06151418
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Novel hormonal therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Nov 7, 2026, 2:38 PM EST
Terminated No phase listed Observational Accepts healthy volunteers

Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

NCT03065790
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
2-Deoxy-2-[18F]fluoro-D-glucose (FDG)
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Nov 7, 2026, 2:38 PM EST